Rapamycin Responds to Alzheimer’s Disease: A Potential Translational Therapy

References

• Hogh P. [Alzheimer’s disease]. Ugeskr Laeger. 2017;179(12):V09160686. Danish.
   PubMedGoogle Scholar
• Collaborators GBDDF. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7(2):e105–e125. doi:10.1016/S2468-2667(21)00249-8
   PubMed Web of Science ®Google Scholar
• Kaeberlein M, Galvan V. Rapamycin and Alzheimer’s disease: time for a clinical trial? Sci Transl Med. 2019;11(476):eaar4289. doi:10.1126/scitranslmed.aar4289
   PubMed Web of Science ®Google Scholar
• Maiese K. Stem cell guidance through the mechanistic target of rapamycin. World J Stem Cells. 2015;7(7):999–1009. doi:10.4252/wjsc.v7.i7.999
   PubMed Web of Science ®Google Scholar
• Chang YF, Hu WM. [Roles of mammalian target of rapamycin signaling and autophagy pathway in Alzheimer’s disease]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2019;41(2):248–255. Chinese. doi:10.3881/j.issn.1000-503X.10802
   PubMedGoogle Scholar
• Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392–395. doi:10.1038/nature08221
   PubMed Web of Science ®Google Scholar
• Selvarani R, Mohammed S, Richardson A. Effect of rapamycin on aging and age-related diseases-past and future. Geroscience. 2021;43(3):1135–1158. doi:10.1007/s11357-020-00274-1
   PubMed Web of Science ®Google Scholar
• Kaeberlein M. Translational geroscience: a new paradigm for 21(st) century medicine. Transl Med Aging. 2017;1:1–4. doi:10.1016/j.tma.2017.09.004
   PubMedGoogle Scholar
• Spilman P, Podlutskaya N, Hart MJ, et al. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer’s disease. PLoS One. 2010;5(4):e9979. doi:10.1371/journal.pone.0009979
   PubMed Web of Science ®Google Scholar
• Lin AL, Zheng W, Halloran JJ, et al. Chronic rapamycin restores brain vascular integrity and function through NO synthase activation and improves memory in symptomatic mice modeling Alzheimer’s disease. J Cereb Blood Flow Metab. 2013;33(9):1412–1421. doi:10.1038/jcbfm.2013.82
   PubMed Web of Science ®Google Scholar
• Pierce A, Podlutskaya N, Halloran JJ, et al. Over-expression of heat shock factor 1 phenocopies the effect of chronic inhibition of TOR by rapamycin and is sufficient to ameliorate Alzheimer’s-like deficits in mice modeling the disease. J Neurochem. 2013;124(6):880–893. doi:10.1111/jnc.12080
   PubMed Web of Science ®Google Scholar
• Chen J, Long Z, Li Y, Luo M, Luo S, He G. Alteration of the Wnt/GSK3beta/beta-catenin signalling pathway by rapamycin ameliorates pathology in an Alzheimer’s disease model. Int J Mol Med. 2019;44(1):313–323. doi:10.3892/ijmm.2019.4198
   PubMed Web of Science ®Google Scholar
• Richardson A, Galvan V, Lin AL, Oddo S. How longevity research can lead to therapies for Alzheimer’s disease: the rapamycin story. Exp Gerontol. 2015;68:51–58. doi:10.1016/j.exger.2014.12.002
   PubMed Web of Science ®Google Scholar
• Li L, Zhang S, Zhang X, et al. Autophagy enhancer carbamazepine alleviates memory deficits and cerebral amyloid-beta pathology in a mouse model of Alzheimer’s disease. Curr Alzheimer Res. 2013;10(4):433–441. doi:10.2174/1567205011310040008
   PubMed Web of Science ®Google Scholar
• Son SM, Song H, Byun J, et al. Altered APP processing in insulin-resistant conditions is mediated by autophagosome accumulation via the inhibition of mammalian target of rapamycin pathway. Diabetes. 2012;61(12):3126–3138. doi:10.2337/db11-1735
   PubMed Web of Science ®Google Scholar
• Caccamo A, Maldonado MA, Majumder S, et al. Naturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism. J Biol Chem. 2011;286(11):8924–8932. doi:10.1074/jbc.M110.180638
   PubMed Web of Science ®Google Scholar
• Medvedik O, Lamming DW, Kim KD, Sinclair DA. MSN2 and MSN4 link calorie restriction and TOR to sirtuin-mediated lifespan extension in Saccharomyces cerevisiae. PLoS Biol. 2007;5(10):e261. doi:10.1371/journal.pbio.0050261
   PubMed Web of Science ®Google Scholar
• Bonda DJ, Lee HG, Camins A, et al. The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations. Lancet Neurol. 2011;10(3):275–279. doi:10.1016/S1474-4422(11)70013-8
   PubMed Web of Science ®Google Scholar
• Caccamo A, Majumder S, Richardson A, Strong R, Oddo S. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J Biol Chem. 2010;285(17):13107–13120. doi:10.1074/jbc.M110.100420
   PubMed Web of Science ®Google Scholar
• Xue Z, Zhang S, Huang L, He Y, Fang R, Fang Y. Increased expression of Beclin-1-dependent autophagy protects against beta-amyloid-induced cell injury in PC12 cells [corrected]. J Mol Neurosci. 2013;51(1):180–186. doi:10.1007/s12031-013-9974-y
   PubMed Web of Science ®Google Scholar
• Ghosh HS, McBurney M, Robbins PD. SIRT1 negatively regulates the mammalian target of rapamycin. PLoS One. 2010;5(2):e9199. doi:10.1371/journal.pone.0009199
   PubMed Web of Science ®Google Scholar
• El-Ami T, Moll L, Carvalhal Marques F, Volovik Y, Reuveni H, Cohen E. A novel inhibitor of the insulin/IGF signaling pathway protects from age-onset, neurodegeneration-linked proteotoxicity. Aging Cell. 2014;13(1):165–174. doi:10.1111/acel.12171
   PubMed Web of Science ®Google Scholar
• Moll L, Ben-Gedalya T, Reuveni H, Cohen E. The inhibition of IGF-1 signaling promotes proteostasis by enhancing protein aggregation and deposition. FASEB J. 2016;30(4):1656–1669. doi:10.1096/fj.15-281675
   PubMed Web of Science ®Google Scholar
• Vingtdeux V, Chandakkar P, Zhao H, d’Abramo C, Davies P, Marambaud P. Novel synthetic small-molecule activators of AMPK as enhancers of autophagy and amyloid-beta peptide degradation. FASEB J. 2011;25(1):219–231. doi:10.1096/fj.10-167361
   PubMed Web of Science ®Google Scholar
• Tang Z, Ioja E, Bereczki E, et al. mTor mediates tau localization and secretion: implication for Alzheimer’s disease. Biochim Biophys Acta. 2015;1853(7):1646–1657. doi:10.1016/j.bbamcr.2015.03.003
   PubMed Web of Science ®Google Scholar
• Shen W, Lu K, Wang J, Wu A, Yue Y. Activation of mTOR signaling leads to orthopedic surgery-induced cognitive decline in mice through beta-amyloid accumulation and tau phosphorylation. Mol Med Rep. 2016;14(4):3925–3934. doi:10.3892/mmr.2016.5700
   PubMed Web of Science ®Google Scholar
• An WL, Cowburn RF, Li L, et al. Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer’s disease. Am J Pathol. 2003;163(2):591–607. doi:10.1016/S0002-9440(10)63687-5
   PubMed Web of Science ®Google Scholar
• Pei JJ, Hugon J. mTOR-dependent signalling in Alzheimer’s disease. J Cell Mol Med. 2008;12(6B):2525–2532. doi:10.1111/j.1582-4934.2008.00509.x
   PubMed Web of Science ®Google Scholar
• Li X, Alafuzoff I, Soininen H, Winblad B, Pei JJ. Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer’s disease brain. FEBS J. 2005;272(16):4211–4220. doi:10.1111/j.1742-4658.2005.04833.x
   PubMed Web of Science ®Google Scholar
• Li X, An WL, Alafuzoff I, Soininen H, Winblad B, Pei JJ. Phosphorylated eukaryotic translation factor 4E is elevated in Alzheimer brain. Neuroreport. 2004;15(14):2237–2240. doi:10.1097/00001756-200410050-00019
   PubMed Web of Science ®Google Scholar
• Meske V, Albert F, Ohm TG. Coupling of mammalian target of rapamycin with phosphoinositide 3-kinase signaling pathway regulates protein phosphatase 2A- and glycogen synthase kinase-3 -dependent phosphorylation of Tau. J Biol Chem. 2008;283(1):100–109. doi:10.1074/jbc.M704292200
   PubMed Web of Science ®Google Scholar
• Cai Z, Zhao B, Li K, et al. Mammalian target of rapamycin: a valid therapeutic target through the autophagy pathway for Alzheimer’s disease? J Neurosci Res. 2012;90(6):1105–1118. doi:10.1002/jnr.23011
   PubMed Web of Science ®Google Scholar
• Heras-Sandoval D, Perez-Rojas JM, Hernandez-Damian J, Pedraza-Chaverri J. The role of PI3K/AKT/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration. Cell Signal. 2014;26(12):2694–2701. doi:10.1016/j.cellsig.2014.08.019
   PubMed Web of Science ®Google Scholar
• Liu Y, Su Y, Wang J, et al. Rapamycin decreases tau phosphorylation at Ser214 through regulation of cAMP-dependent kinase. Neurochem Int. 2013;62(4):458–467. doi:10.1016/j.neuint.2013.01.014
   PubMed Web of Science ®Google Scholar
• Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer’s disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol. 2021;20(1):68–80. doi:10.1016/S1474-4422(20)30412-9
   PubMed Web of Science ®Google Scholar
• Hays CC, Zlatar ZZ, Meloy MJ, et al. APOE modifies the interaction of entorhinal cerebral blood flow and cortical thickness on memory function in cognitively normal older adults. Neuroimage. 2019;202:116162. doi:10.1016/j.neuroimage.2019.116162
   PubMed Web of Science ®Google Scholar
• Thambisetty M, Beason-Held L, An Y, Kraut MA, Resnick SM. APOE epsilon4 genotype and longitudinal changes in cerebral blood flow in normal aging. Arch Neurol. 2010;67(1):93–98. doi:10.1001/archneurol.2009.913
   PubMedGoogle Scholar
• Persson J, Lind J, Larsson A, et al. Altered brain white matter integrity in healthy carriers of the APOE epsilon4 allele: a risk for AD? Neurology. 2006;66(7):1029–1033. doi:10.1212/01.wnl.0000204180.25361.48
   PubMed Web of Science ®Google Scholar
• Lin AL, Butterfield DA, Richardson A. mTOR: alzheimer’s disease prevention for APOE4 carriers. Oncotarget. 2016;7(29):44873–44874. doi:10.18632/oncotarget.10349
   PubMedGoogle Scholar
• Lin AL, Jahrling JB, Zhang W, et al. Rapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer’s disease. J Cereb Blood Flow Metab. 2017;37(1):217–226. doi:10.1177/0271678X15621575
   PubMed Web of Science ®Google Scholar
• Yamazaki Y, Zhao N, Caulfield TR, Liu CC, Bu G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol. 2019;15(9):501–518. doi:10.1038/s41582-019-0228-7
   PubMed Web of Science ®Google Scholar
• Lin AL, Parikh I, Yanckello LM, et al. APOE genotype-dependent pharmacogenetic responses to rapamycin for preventing Alzheimer’s disease. Neurobiol Dis. 2020;139:104834. doi:10.1016/j.nbd.2020.104834
   PubMed Web of Science ®Google Scholar
• Tai LM, Balu D, Avila-Munoz E, et al. EFAD transgenic mice as a human APOE relevant preclinical model of Alzheimer’s disease. J Lipid Res. 2017;58(9):1733–1755. doi:10.1194/jlr.R076315
   PubMed Web of Science ®Google Scholar
• Hampel H, Caraci F, Cuello AC, et al. A path toward precision medicine for neuroinflammatory mechanisms in Alzheimer’s disease. Front Immunol. 2020;11:456. doi:10.3389/fimmu.2020.00456
   PubMed Web of Science ®Google Scholar
• Piekut T, Hurla M, Banaszek N, et al. Infectious agents and Alzheimer’s disease. J Integr Neurosci. 2022;21(2):73. doi:10.31083/j.jin2102073
   PubMed Web of Science ®Google Scholar
• Bettcher BM, Tansey MG, Dorothee G, Heneka MT. Peripheral and central immune system crosstalk in Alzheimer disease - a research prospectus. Nat Rev Neurol. 2021;17(11):689–701. doi:10.1038/s41582-021-00549-x
   PubMed Web of Science ®Google Scholar
• Zhou M, Xu W, Wang J, et al. Boosting mTOR-dependent autophagy via upstream TLR4-MyD88-MAPK signalling and downstream NF-kappaB pathway quenches intestinal inflammation and oxidative stress injury. EBioMedicine. 2018;35:345–360. doi:10.1016/j.ebiom.2018.08.035
   PubMed Web of Science ®Google Scholar
• Liu YC, Gao XX, Chen L, You XQ. Rapamycin suppresses Abeta25-35- or LPS-induced neuronal inflammation via modulation of NF-kappaB signaling. Neuroscience. 2017;355:188–199. doi:10.1016/j.neuroscience.2017.05.005
   PubMed Web of Science ®Google Scholar
• Zhang Y, He X, Wu X, et al. Rapamycin upregulates glutamate transporter and IL-6 expression in astrocytes in a mouse model of Parkinson’s disease. Cell Death Dis. 2017;8(2):e2611. doi:10.1038/cddis.2016.491
   PubMedGoogle Scholar
• Ringheim GE, Szczepanik AM, Petko W, Burgher KL, Zhu SZ, Chao CC. Enhancement of beta-amyloid precursor protein transcription and expression by the soluble interleukin-6 receptor/interleukin-6 complex. Brain Res Mol Brain Res. 1998;55(1):35–44. doi:10.1016/s0169-328x(97)00356-2
   PubMedGoogle Scholar
• Erta M, Quintana A, Hidalgo J. Interleukin-6, a major cytokine in the central nervous system. Int J Biol Sci. 2012;8(9):1254–1266. doi:10.7150/ijbs.4679
   PubMed Web of Science ®Google Scholar
• Chapman NM, Chi H. mTOR signaling, Tregs and immune modulation. Immunotherapy. 2014;6(12):1295–1311. doi:10.2217/imt.14.84
   PubMed Web of Science ®Google Scholar
• Mandrioli J, D’Amico R, Zucchi E, et al. Rapamycin treatment for amyotrophic lateral sclerosis: protocol for a Phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial). Medicine. 2018;97(24):e11119. doi:10.1097/MD.0000000000011119
   PubMed Web of Science ®Google Scholar
• Faridar A, Thome AD, Zhao W, et al. Restoring regulatory T-cell dysfunction in Alzheimer’s disease through ex vivo expansion. Brain Commun. 2020;2(2):fcaa112. doi:10.1093/braincomms/fcaa112
   PubMedGoogle Scholar
• Van Skike CE, Jahrling JB, Olson AB, et al. Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer’s disease and vascular cognitive impairment. Am J Physiol Heart Circ Physiol. 2018;314(4):H693–H703. doi:10.1152/ajpheart.00570.2017
   PubMed Web of Science ®Google Scholar
• Towner RA, Gulej R, Zalles M, et al. Rapamycin restores brain vasculature, metabolism, and blood-brain barrier in an inflammaging model. Geroscience. 2021;43(2):563–578. doi:10.1007/s11357-021-00363-9
   PubMed Web of Science ®Google Scholar
• Van Skike CE, Lin AL, Roberts burbank R, et al. mTOR drives cerebrovascular, synaptic, and cognitive dysfunction in normative aging. Aging Cell. 2020;19(1):e13057. doi:10.1111/acel.13057
   PubMed Web of Science ®Google Scholar
• Wang X, Xia W, Li K, Zhang Y, Ge W, Ma C. Rapamycin regulates cholesterol biosynthesis and cytoplasmic ribosomal proteins in hippocampus and temporal lobe of APP/PS1 mouse. J Neurol Sci. 2019;399:125–139. doi:10.1016/j.jns.2019.02.022
   PubMed Web of Science ®Google Scholar
• Caccamo A, De Pinto V, Messina A, Branca C, Oddo S. Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer’s disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature. J Neurosci. 2014;34(23):7988–7998. doi:10.1523/JNEUROSCI.0777-14.2014
   PubMed Web of Science ®Google Scholar
• Wang H, Fu J, Xu X, Yang Z, Zhang T. Rapamycin activates mitophagy and alleviates cognitive and synaptic plasticity deficits in a mouse model of Alzheimer’s disease. J Gerontol a Biol Sci Med Sci. 2021;76(10):1707–1713. doi:10.1093/gerona/glab142
   PubMed Web of Science ®Google Scholar
• Li S, Selkoe DJ. A mechanistic hypothesis for the impairment of synaptic plasticity by soluble Abeta oligomers from Alzheimer’s brain. J Neurochem. 2020;154(6):583–597. doi:10.1111/jnc.15007
   PubMed Web of Science ®Google Scholar
• O’Neill C, Kiely AP, Coakley MF, Manning S, Long-Smith CM. Insulin and IGF-1 signalling: longevity, protein homoeostasis and Alzheimer’s disease. Biochem Soc Trans. 2012;40(4):721–727. doi:10.1042/BST20120080
   PubMed Web of Science ®Google Scholar
• Tang SJ, Reis G, Kang H, Gingras AC, Sonenberg N, Schuman EM. A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc Natl Acad Sci U S A. 2002;99(1):467–472. doi:10.1073/pnas.012605299
   PubMed Web of Science ®Google Scholar
• Garelick MG, Kennedy BK. TOR on the brain. Exp Gerontol. 2011;46(2–3):155–163. doi:10.1016/j.exger.2010.08.030
   PubMed Web of Science ®Google Scholar
• Ehninger D, Han S, Shilyansky C, et al. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med. 2008;14(8):843–848. doi:10.1038/nm1788
   PubMed Web of Science ®Google Scholar
• Majumder S, Richardson A, Strong R, Oddo S. Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. PLoS One. 2011;6(9):e25416. doi:10.1371/journal.pone.0025416
   PubMed Web of Science ®Google Scholar
• Whitesell JD, Buckley AR, Knox JE, et al. Whole brain imaging reveals distinct spatial patterns of amyloid beta deposition in three mouse models of Alzheimer’s disease. J Comp Neurol. 2019;527(13):2122–2145. doi:10.1002/cne.24555
   PubMed Web of Science ®Google Scholar
• Kam TI, Gwon Y, Jung YK. Amyloid beta receptors responsible for neurotoxicity and cellular defects in Alzheimer’s disease. Cell Mol Life Sci. 2014;71(24):4803–4813. doi:10.1007/s00018-014-1706-0
   PubMed Web of Science ®Google Scholar
• Khonsari F, Heydari M, Sharifzadeh M, Valizadeh H, Dinarvand R, Atyabi F. Transferrin decorated-nanostructured lipid carriers (NLCs) are a promising delivery system for rapamycin in Alzheimer’s disease: an in vivo study. Biomater Adv. 2022;137:212827. doi:10.1016/j.bioadv.2022.212827
   PubMedGoogle Scholar
• Xu S, Yang P, Qian K, et al. Modulating autophagic flux via ROS-responsive targeted micelles to restore neuronal proteostasis in Alzheimer’s disease. Bioact Mater. 2022;11:300–316. doi:10.1016/j.bioactmat.2021.09.017
   PubMed Web of Science ®Google Scholar
• Querfurth H, Lee HK. Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration. Mol Neurodegener. 2021;16(1):44. doi:10.1186/s13024-021-00428-5
   PubMed Web of Science ®Google Scholar
• Shi Q, Chang C, Saliba A, Bhat MA. Microglial mTOR Activation Upregulates Trem2 and Enhances beta-Amyloid Plaque Clearance in the 5XFAD Alzheimer’s Disease Model. J Neurosci. 2022;42(27):5294–5313. doi:10.1523/JNEUROSCI.2427-21.2022
   PubMed Web of Science ®Google Scholar
• Zhang Z, Yan J, Bowman AB, Bryan MR, Singh R, Aschner M. Dysregulation of TFEB contributes to manganese-induced autophagic failure and mitochondrial dysfunction in astrocytes. Autophagy. 2020;16(8):1506–1523. doi:10.1080/15548627.2019.1688488
   PubMed Web of Science ®Google Scholar
• Zoungrana LI, Krause-Hauch M, Wang H, et al. The interaction of mTOR and Nrf2 in neurogenesis and its implication in neurodegenerative diseases. Cells. 2022;11(13):2048.
   PubMed Web of Science ®Google Scholar
• Tramutola A, Lanzillotta C, Di Domenico F. Targeting mTOR to reduce Alzheimer-related cognitive decline: from current hits to future therapies. Expert Rev Neurother. 2017;17(1):33–45. doi:10.1080/14737175.2017.1244482
   PubMed Web of Science ®Google Scholar
• Ma T, Hoeffer CA, Capetillo-Zarate E, et al. Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer’s disease. PLoS One. 2010;5(9):e12845.
   PubMed Web of Science ®Google Scholar
• Carosi JM, Sargeant TJ. Rapamycin and Alzheimer disease: a double-edged sword? Autophagy. 2019;15(8):1460–1462. doi:10.1080/15548627.2019.1615823
   PubMed Web of Science ®Google Scholar
• Carosi JM, Sargeant TJ. Rapamycin and Alzheimer disease: a hypothesis for the effective use of rapamycin for treatment of neurodegenerative disease. Autophagy. 2023;19(8):2386–2390. doi:10.1080/15548627.2023.2175569
   PubMed Web of Science ®Google Scholar
• Norwitz NG, Querfurth H. mTOR mysteries: nuances and questions about the mechanistic target of rapamycin in neurodegeneration. Front Neurosci. 2020;14:775. doi:10.3389/fnins.2020.00775
   PubMed Web of Science ®Google Scholar
• Arriola Apelo SI, Lamming DW. Rapamycin: an InhibiTOR of aging emerges from the soil of Easter Island. J Gerontol a Biol Sci Med Sci. 2016;71(7):841–849. doi:10.1093/gerona/glw090
   PubMed Web of Science ®Google Scholar
• Sarlus H, Heneka MT. Microglia in Alzheimer’s disease. J Clin Invest. 2017;127(9):3240–3249. doi:10.1172/JCI90606
   PubMed Web of Science ®Google Scholar